217 related articles for article (PubMed ID: 22109348)
21. LDL reduction: how low should we go and is it safe?
Robinson JG
Curr Cardiol Rep; 2008 Nov; 10(6):481-7. PubMed ID: 18950559
[TBL] [Abstract][Full Text] [Related]
22. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
23. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic options to further lower C-reactive protein for patients on statin treatment.
Joshi PH; Jacobson TA
Curr Atheroscler Rep; 2010 Jan; 12(1):34-42. PubMed ID: 20425269
[TBL] [Abstract][Full Text] [Related]
26. Getting there: statin plus ezetimibe for low-density lipoprotein cholesterol goals.
Hurley DL; Isley WL
Mayo Clin Proc; 2005 May; 80(5):585-6. PubMed ID: 15887424
[No Abstract] [Full Text] [Related]
27. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
[TBL] [Abstract][Full Text] [Related]
28. Clinical use of ezetimibe.
Cheng AY; Leiter LA
Can J Clin Pharmacol; 2003; 10 Suppl A():21A-5A. PubMed ID: 14571302
[TBL] [Abstract][Full Text] [Related]
29. LDL cholesterol goals in high-risk patients: how low do we go and how do we get there?
Besseling J; van Capelleveen J; Kastelein JJ; Hovingh GK
Drugs; 2013 Mar; 73(4):293-301. PubMed ID: 23494186
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On Study.
Bissonnette S; Habib R; Sampalis F; Boukas S; Sampalis JS;
Can J Cardiol; 2006 Oct; 22(12):1035-44. PubMed ID: 17036098
[TBL] [Abstract][Full Text] [Related]
31. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
32. Management of hypercholesterolaemia in postmenopausal women.
Davidson MH; Maki KC; Karp SK; Ingram KA
Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
[TBL] [Abstract][Full Text] [Related]
33. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
O'Keefe JH; DiNicolantonio JJ; Lavie CJ
Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
[TBL] [Abstract][Full Text] [Related]
34. Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.
Descamps O; Tomassini JE; Lin J; Polis AB; Shah A; Brudi P; Hanson ME; Tershakovec AM
Atherosclerosis; 2015 Jun; 240(2):482-9. PubMed ID: 25913444
[TBL] [Abstract][Full Text] [Related]
35. Resistance and intolerance to statins.
Reiner Z
Nutr Metab Cardiovasc Dis; 2014 Oct; 24(10):1057-66. PubMed ID: 24996502
[TBL] [Abstract][Full Text] [Related]
36. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
37. [Update of planning tables of cholesterol-lowering therapy orientated to achieve LDL therapeutic targets].
Masana L; Plana N
Clin Investig Arterioscler; 2015; 27(3):138-43. PubMed ID: 25865752
[TBL] [Abstract][Full Text] [Related]
38. Management of dyslipidemia in the high-risk patient.
Stein EA
Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy.
González CA; Rubio-Guerra AF; Pavía A; Redding FJ; Cervantes JL; Zacarías JL; Yza R; Carranza J; Fernández P; Morales E; Robles FJ; Leyva JL; Rodríguez L
Clin Drug Investig; 2007; 27(5):333-7. PubMed ID: 17451281
[TBL] [Abstract][Full Text] [Related]
40. A 10-year experience using combined lipid-lowering pharmacotherapy in children and adolescents.
Araujo MB; Pacce MS
J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1285-1291. PubMed ID: 27718491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
